Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for preclinical obesity drug LX9851.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a presentation at the 24th Annual Needham Virtual Healthcare Conference 2025 on Wednesday, ...
Five of the Flames’ final eight games will be played at the Scotiabank Saddledome, including a head-to-head matchup with one ...
Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide
Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...
Lexicon Pharmaceuticals, Inc.’s LXRX share price has surged by 77.50%, which has investors questioning if this is right time ...
Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...
In the assessment of 12-month price targets, analysts unveil insights for Lexicon Pharmaceuticals, presenting an average ...
Lexicon Pharmaceuticals granted Novo Nordisk exclusive rights to develop LX9851, an oral obesity drug, with potential ...
HC Wainwright reiterated their buy rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback